|
FDA Grants Priority Review to Dupilumab for Children with Atopic Dermatitis
|
 If approved, dupilumab (Dupixent, Regeneron and Sanofi) would be indicated for use as an add-on maintenance treatment for children ages 6 to 11 years with moderate-to-severe atopic dermatitis.
|
|
Read more
|
